310 related articles for article (PubMed ID: 31849282)
21. Cost-effectiveness analysis of CYP2C19 genotype-guided antiplatelet therapy for patients with acute minor ischemic stroke and high-risk transient ischemic attack in China.
Zhang Z; Bao Y; Gu Y; Zhang M; Li X
Br J Clin Pharmacol; 2024 Feb; 90(2):483-492. PubMed ID: 37795861
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.
Dong OM; Friede KA; Chanfreau-Coffinier C; Voora D
Eur Heart J Qual Care Clin Outcomes; 2023 Apr; 9(3):249-257. PubMed ID: 35652783
[TBL] [Abstract][Full Text] [Related]
23. Risk of major adverse cardiovascular events of
Biswas M; Kali MSK; Biswas TK; Ibrahim B
Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
[TBL] [Abstract][Full Text] [Related]
24. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Johnson SG; Gruntowicz D; Chua T; Morlock RJ
J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
[TBL] [Abstract][Full Text] [Related]
25. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.
Crespin DJ; Federspiel JJ; Biddle AK; Jonas DE; Rossi JS
Value Health; 2011 Jun; 14(4):483-91. PubMed ID: 21669373
[TBL] [Abstract][Full Text] [Related]
26. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
27. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y
Zhang Y; Shi XJ; Peng WX; Han JL; Lin BD; Zhang R; Zhang YN; Yan JL; Wei JJ; Wang YF; Chen SW; Nan N; Fang ZW; Zeng Y; Lin Y
Front Pharmacol; 2020; 11():582929. PubMed ID: 33551797
[No Abstract] [Full Text] [Related]
28. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
29. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
[TBL] [Abstract][Full Text] [Related]
30. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
Jiang M; You JH
Pharmacogenomics; 2016 May; 17(7):701-13. PubMed ID: 27167099
[TBL] [Abstract][Full Text] [Related]
32. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Chin CT; Mellstrom C; Chua TS; Matchar DB
Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
[TBL] [Abstract][Full Text] [Related]
33. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
34. Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
Claassens DMF; Gimbel ME; Bergmeijer TO; Vos GJA; Hermanides RS; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; de Vrey EA; Heestermans TACM; Jukema JW; von Birgelen C; Waalewijn RA; Hofma SH; den Hartog FR; Voskuil M; Van't Hof AWJ; Asselbergs FW; Mosterd A; Herrman JR; Dewilde W; Mahmoodi BK; Deneer VHM; Ten Berg JM
Int J Cardiol; 2021 Jul; 334():10-17. PubMed ID: 33887342
[TBL] [Abstract][Full Text] [Related]
35. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
[TBL] [Abstract][Full Text] [Related]
36. Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack.
Narasimhalu K; Chan J; Ang YK; De Silva DA; Tan KB
Int J Stroke; 2024 Feb; 19(2):209-216. PubMed ID: 37679898
[TBL] [Abstract][Full Text] [Related]
37. Effects of the
Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Gasche D; Ulle T; Meier B; Greiner RA
Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294
[TBL] [Abstract][Full Text] [Related]
39. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Lala A; Berger JS; Sharma G; Hochman JS; Scott Braithwaite R; Ladapo JA
J Thromb Haemost; 2013 Jan; 11(1):81-91. PubMed ID: 23137413
[TBL] [Abstract][Full Text] [Related]
40. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
